CMAC’s vision is to revolutionise the way pharmaceuticals and high-value products are developed and made through the use of digital twins and microfactories. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Lilly, Novartis, Pfizer, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, postdocs, and PhD students. CMAC delivers a successful doctoral training centre with over 100 PhDs recruited to date and the world-class CMAC National Facility hosted within the Technology and Innovation Centre (TIC) at the University of Strathclyde offering access to academic and industrial users to state-of-the art processing, analysis and characterisation.


23 September 2021